📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-31 12:58
709 analysed today
709
Today
133,598
All-time analysed
40,124
Positive
6,284
Negative
79,370
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Balaxi Secures WHO-GMP Certification for Jadcherla Facility Valid Till August 2029
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Jadcherla, Hyderabad. The certification was granted by the Licensing Authority, Government of Telangana, on August 27, 2026 (valid until August 26, 2029), following an inspection on July 14, 2026. The company has commenced manufacturing of initially approved products and plans to expand the facility's portfolio for international markets. This marks a key step in Balaxi's transition to in-house manufacturing to aid margin recovery from its current TTM OPM of 3.2%.
Confidence: HIGH
What changedBalaxi obtained WHO-GMP approval for its newly established Jadcherla formulation facility and initiated commercial production.
Why it mattersIn-house WHO-GMP manufacturing validates quality standards for target export markets and supports the transition to higher-margin formulation manufacturing.
Certificate Validity: 27th August, 2026 to 26th August, 2029Inspection Date: 14th July, 2026TTM Revenue: ₹280 CrTTM Operating Margin: 3.2%
📅 Short termPositive operational milestone confirming compliance and enabling output ramp-up from the Jadcherla facility.
📈 Long termEnhances export credentials and margin profile over future quarters as more formulations are cleared and manufactured in-house.
⚠ Risk flags
- High geographic revenue concentration (over 50% from Angola)
- Regulatory approval timelines for additional formulation products
- Plant utilization and execution risks during initial ramp-up
Key Highlights
Received WHO-GMP certification for its first formulation plant at Jadcherla, Hyderabad
Certification issued on 27th August, 2026, and valid for 3 years up to 26th August, 2029
Inspection successfully conducted by Licensing Authority, Government of Telangana on 14th July, 2026
Commenced commercial manufacturing of initial approved products with further product additions in the pipeline
👀 What to Watch
Track capacity utilization, product approvals for international target markets, and margin expansion in subsequent quarterly results.
Balaxi Q1 FY27 PAT Jumps 347% to ₹1.29 Cr; Jadcherla Plant Commences Production
Balaxi Pharmaceuticals reported a 14.1% YoY revenue growth to ₹80.68 crore for Q1 FY27, with PAT surging 347% to ₹1.29 crore from a low base of ₹0.29 crore. A key milestone was the commencement of commercial production at its first manufacturing facility in Jadcherla, Hyderabad, which currently has 31 product approvals. While gross margins improved to 46.5%, EBITDA margins remained relatively flat at 5.8% as the company navigates a shift toward institutional business. The company continues to expand its Latin American footprint, which now contributes 46% of the pharmaceutical product mix.
Confidence: HIGH
What changedThe company has transitioned from an 'Asset Light' outsourced model to an 'Asset Right' model with its own manufacturing facility and reported a significant recovery in quarterly net profit.
Why it mattersBackward integration through the new Hyderabad plant is intended to improve supply chain control and long-term margins, which have been under pressure due to currency volatility and a shift in business mix.
Q1 FY27 Revenue: ₹80.68 CrQ1 FY27 PAT: ₹1.29 CrRevenue vs TTM Revenue: 29.8%Gross Margin: 46.5%EBITDA Margin: 5.8%Total Product Registrations: 980
📅 Short termThe commencement of the new plant and the sharp YoY jump in PAT are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe structural shift to in-house manufacturing could lead to margin expansion and reduced dependency on external suppliers over the next 2-3 years if execution remains on track.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High geographic concentration in Angola (54% of mix)
- Currency volatility risks in frontier markets
- Low EBITDA margins compared to historical levels
Key Highlights
Consolidated revenue increased 14.1% YoY to ₹80.68 crore in Q1 FY27 from ₹70.74 crore.
Net profit (PAT) rose to ₹1.29 crore, a 347% increase compared to ₹0.29 crore in the previous year's quarter.
Commenced commercial production at the new Jadcherla formulation facility with 31 commercial product approvals.
Total product portfolio reached 980 registrations across seven countries, with 16 new registrations added in Q1.
Gross profit margin expanded by 241 basis points to 46.5%, though EBITDA margin stayed compressed at 5.8%.
👀 What to Watch
Investors should monitor the utilization levels and margin impact of the new Jadcherla facility as it scales up. The upcoming WHO-GMP certification for this plant is a critical milestone to watch for entering more regulated markets.
31 Product Approvals & Commercial Production Start at Jadcherla Plant; Q1 Revenue Rs 80.68 Cr
Balaxi Pharmaceuticals has officially commenced commercial production at its first in-house formulation plant in Jadcherla, Hyderabad, starting with two products. The company has secured manufacturing permissions for a total of 31 products and completed a WHO-GMP audit in July 2026, with the CAPA response already submitted. Consolidated revenue for Q1 FY27 rose to Rs 80.68 Cr, up 14% YoY from Rs 70.74 Cr, although standalone operations recorded a net loss of Rs 1.25 Cr due to initial plant-related expenses. This transition from an 'Asset Right' model to in-house manufacturing is a pivotal shift for the company's margin profile.
Confidence: HIGH
What changedThe company has transitioned from a distribution-led 'Asset Right' model to an active manufacturer with the commissioning of its first formulation plant.
Why it mattersIn-house manufacturing allows the company to capture higher margins and better control its supply chain, which is critical given its high geographic concentration in markets like Angola.
Total Approved Products: 31Q1 Consolidated Revenue: Rs 80.68 CrQ1 Standalone Net Loss: Rs 1.25 CrRevenue vs Market Cap: ~61.5%YoY Revenue Growth: 14%
📅 Short termThe start of commercial production is a positive operational milestone that may support the stock price, though the standalone loss highlights the near-term cost of scaling up.
📈 Long termSecuring WHO-GMP certification and utilizing the Jadcherla plant for its LATAM and African exports could structurally improve profitability and re-rate the company from a trader to a manufacturer.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Standalone losses during the plant ramp-up phase
- Regulatory risk if WHO-GMP certification is delayed
- High geographic concentration in Angola
Key Highlights
Successfully commenced commercial production at the Jadcherla facility with Paracetamol Tablets and Piroxicam Capsules.
Received manufacturing permissions for an additional 29 products, bringing the total approved portfolio to 31 products.
Consolidated Q1 FY27 revenue grew to Rs 80.68 Cr, representing a 14% increase over the Rs 70.74 Cr reported in Q1 FY26.
WHO-GMP audit conducted in July 2026 by CDSCO and State FDA; CAPA response submitted for final certification.
Standalone net loss of Rs 1.25 Cr reported for the quarter, reflecting the impact of depreciation and administrative costs of the new facility.
👀 What to Watch
Monitor the timeline for receiving the formal WHO-GMP certification and the progressive launch of the 29 newly approved products. Investors should track if the shift to in-house manufacturing successfully lifts the consolidated operating margin from its current low of 3.2%.
Balaxi Pharma Q1 Revenue Rs 80.68 Cr; Jadcherla Plant Starts Commercial Production
Balaxi Pharmaceuticals reported a 14% YoY increase in consolidated revenue to Rs 80.68 Cr for Q1 FY27. A major milestone was achieved with the commencement of commercial production at its first manufacturing facility in Jadcherla, Hyderabad, initially launching two products. While the consolidated operations remain profitable, the standalone entity reported a net loss of Rs 1.25 Cr, reflecting the high initial costs of operationalizing the new plant. The company is now awaiting WHO-GMP certification following a regulatory audit in July 2026.
Confidence: HIGH
What changedThe company has transitioned from a pure distribution model to an integrated manufacturing-cum-distribution model with the start of its Jadcherla plant.
Why it mattersIn-house manufacturing is critical for Balaxi to recover its EBITDA margins, which have compressed from historical 15% levels to approximately 3% due to institutional sales and currency volatility in Angola.
Consolidated Revenue (Q1 FY27): Rs 80.68 CrStandalone Net Loss (Q1 FY27): Rs 1.25 CrApproved Product Count: 31Q1 Revenue vs TTM Revenue: 29.8%Subsidiary Net Profit: Rs 2.07 Cr
📅 Short termThe market may react cautiously to the standalone loss and the pending final WHO-GMP certification, despite the revenue growth.
📈 Long termThe Jadcherla plant is a structural pivot; if successful, it allows the company to capture higher margins and expand more aggressively into LATAM markets.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Standalone net loss indicating high initial plant overheads
- Regulatory risk pending final WHO-GMP certification
- High geographic concentration in Angola
Key Highlights
Consolidated revenue grew to Rs 80.68 Cr in Q1 FY27 from Rs 70.74 Cr in the same quarter last year.
Jadcherla facility commenced production with Paracetamol 500mg and Piroxicam 20mg.
Total approved commercial product portfolio expanded to 31 products after receiving 29 new permissions.
Standalone operations recorded a net loss of Rs 1.25 Cr compared to a profit of Rs 0.19 Cr YoY.
WHO-GMP audit by CDSCO and State FDA completed in July 2026; CAPA response has been submitted.
👀 What to Watch
Monitor the timeline for receiving the WHO-GMP certification and the pace at which the 29 newly approved products are integrated into commercial production to improve capacity utilization.
Balaxi Q1 Revenue Up 14% to ₹80.7 Cr; Jadcherla Plant Starts Commercial Production
Balaxi Pharmaceuticals reported a 14% YoY growth in consolidated revenue to ₹80.68 Cr for Q1 FY27. A critical milestone was achieved with the commencement of commercial production at the company's first formulation plant in Jadcherla, Hyderabad, starting with two products. While standalone operations recorded a net loss of ₹1.25 Cr (likely due to plant startup costs), the consolidated entity remains profitable. The company has secured approvals for 31 products at the new facility and is awaiting WHO-GMP certification following a July 2026 audit.
Confidence: HIGH
What changedThe company has transitioned from a distribution-led model to an integrated manufacturer with the operationalization of its first in-house production facility.
Why it mattersIn-house manufacturing is central to Balaxi's strategy to improve EBITDA margins, which have recently been squeezed to ~3% from historical levels of 15% due to institutional sales shifts and currency volatility.
Consolidated Revenue (Q1 FY27): ₹80.68 CrRevenue Growth (YoY): 14.05%Standalone Net Loss: ₹1.25 CrApproved Products (New Plant): 31Q1 Revenue vs TTM Revenue: 29.8%
📅 Short termThe start of commercial production is a positive catalyst that may offset the impact of the standalone quarterly loss in the immediate term.
📈 Long termThe Jadcherla plant is expected to drive margin expansion and reduce dependency on third-party manufacturers, potentially re-rating the business if utilization scales effectively.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High geographic concentration in Angola (>50% revenue)
- Currency volatility risks (Angolan Kwanza)
- Regulatory risk pending final WHO-GMP certification
Key Highlights
Consolidated revenue increased 14.05% YoY to ₹80.68 Cr from ₹70.74 Cr in the previous year's quarter.
Commenced commercial production at the Jadcherla facility with Paracetamol Tablets and Piroxicam Capsules.
Total approved commercial product portfolio for the new plant expanded to 31 products after receiving 29 new permissions.
Standalone net loss of ₹1.25 Cr reported for Q1 FY27, compared to a profit of ₹0.19 Cr in Q1 FY26.
WHO-GMP audit by CDSCO and State FDA completed in July 2026; CAPA response has been submitted for final certification.
👀 What to Watch
Monitor the timeline for receiving the formal WHO-GMP certification and the volume ramp-up of the 29 newly approved products at the Jadcherla facility.
Balaxi Pharma FY26 Revenue Dips 7.7% to ₹270 Cr; PAT Plummets 94% Amid Strategic Shift
Balaxi Pharmaceuticals reported a challenging FY26 with consolidated revenue declining 7.7% YoY to ₹270.17 crore, primarily due to extended working capital cycles in its Angola institutional business. Profitability saw a severe decline, with EBITDA falling 66.1% to ₹11.35 crore and PAT dropping 94.3% to ₹1.42 crore. Despite the bottom-line pressure, the company successfully commissioned its first manufacturing facility in Hyderabad, marking a shift to an 'Asset Right' model. The Latin American (LATAM) segment showed resilience with 11% revenue growth, and the company is exiting its non-core building hardware business to focus entirely on pharmaceuticals.
Key Highlights
FY26 Consolidated Revenue fell 7.7% YoY to ₹270.17 crore, while PAT plummeted 94.3% to ₹1.42 crore.
EBITDA margins contracted significantly from 11.5% in FY25 to 4.2% in FY26 due to higher operational costs and business mix.
LATAM operations grew 11% YoY to ₹111.29 crore, now contributing 48% of total pharmaceutical revenue.
Successfully commissioned the first formulation facility in Hyderabad to drive backward integration and future margin expansion.
Total product portfolio reached 964 registrations across 7 countries with 200+ more in the pipeline.
👀 What to Watch
Investors should exercise caution due to the severe margin compression and working capital issues in Africa, while monitoring the commercialization of the new Hyderabad plant. The strategic exit from non-core businesses and focus on high-margin LATAM markets are positive long-term indicators despite current earnings volatility.
Balaxi Pharma Secures License for New Hyderabad Plant; FY26 Net Profit Drops 94% to ₹1.42 Cr
Balaxi Pharmaceuticals reported a sharp decline in consolidated net profit for FY26, falling to ₹1.42 crore from ₹25.07 crore in the previous year, primarily due to higher administrative and employee costs. Consolidated revenue also saw a decline of 7.6% YoY, reaching ₹270.17 crore. However, the company achieved a major milestone by receiving the manufacturing license for its first pharmaceutical formulation plant at Jadcherla, Hyderabad, on May 23, 2026. The facility is now ready for commercialization of Paracetamol and Piroxicam, with 40 more product permissions currently in progress.
Key Highlights
Consolidated FY26 revenue stood at ₹270.17 crore, down from ₹292.56 crore in FY25.
Consolidated net profit for FY26 plummeted 94% YoY to ₹1.42 crore compared to ₹25.07 crore.
Received manufacturing license for the Jadcherla facility on May 23, 2026, after successful CDSCO inspection and CAPA verification.
Initiated manufacturing product permissions for 40 additional products to support phased expansion.
Total comprehensive income for FY26 was ₹17.34 crore, supported by ₹15.92 crore in foreign currency translation gains.
👀 What to Watch
Investors should closely monitor the commercial ramp-up of the new Jadcherla facility, as the shift to in-house manufacturing is critical to recovering the significant drop in profitability seen this fiscal year. While the manufacturing license is a positive long-term catalyst, the current pressure on margins requires a cautious approach.
Balaxi Pharma FY26 Profit Falls 94% to ₹1.4 Cr; New Hyderabad Plant Receives Mfg License
Balaxi Pharmaceuticals reported a sharp decline in consolidated net profit for FY26, which plummeted to ₹1.42 crore from ₹25.07 crore in the previous fiscal year. Consolidated revenue also saw a contraction, falling 7.6% YoY to ₹270.17 crore. Despite the weak financial performance, the company achieved a major operational milestone by receiving the manufacturing license for its first pharmaceutical formulation plant in Jadcherla, Hyderabad, on May 23, 2026. The facility is now ready for commercialization of Paracetamol and Piroxicam, with 40 additional product permissions currently in process.
Key Highlights
Consolidated Net Profit for FY26 dropped significantly by 94.3% YoY to ₹1.42 crore.
Annual Consolidated Revenue decreased to ₹270.17 crore compared to ₹292.56 crore in FY25.
Received Manufacturing License for the Jadcherla facility on May 23, 2026, following successful CDSCO inspection.
Initiated manufacturing product permissions for 40 additional products to support phased expansion.
Board recommended the re-appointment of Ms. Akshita Ostwal as Independent Director for a second 5-year term.
👀 What to Watch
Investors should exercise caution as the company faces severe margin pressure and a significant drop in profitability. Monitor the commercialization progress of the new Jadcherla plant and WHO-GMP certification as these are critical for a potential recovery in FY27.
Balaxi Pharma FY26 Cons. Profit Falls 94% to ₹1.42 Cr; Jadcherla Plant License Received
Balaxi Pharmaceuticals reported a significant 94.3% decline in consolidated net profit for FY26, dropping to ₹1.42 crore from ₹25.07 crore in FY25, despite only a 7.6% dip in revenue to ₹270.17 crore. The bottom line was heavily impacted by a surge in administrative and employee expenses. On the operational front, the company received its manufacturing license for the Jadcherla facility on May 23, 2026, and is now ready for commercial production of Paracetamol and Piroxicam. The company is also pursuing WHO-GMP certification and has applied for 40 additional product permissions.
Key Highlights
Consolidated Net Profit plummeted 94.3% YoY to ₹1.42 crore in FY26 from ₹25.07 crore.
Consolidated Revenue for the full year decreased by 7.6% YoY to ₹270.17 crore.
Received manufacturing license for the Jadcherla formulation facility on May 23, 2026.
Standalone FY26 Net Profit showed growth, rising to ₹5.15 crore from ₹3.60 crore YoY.
Initiated manufacturing product permissions for 40 additional products to support phased expansion.
👀 What to Watch
The sharp erosion in consolidated profitability is a major concern that outweighs the positive news of the plant license in the short term. Investors should monitor the commercial ramp-up of the Jadcherla facility and margin recovery in upcoming quarters before making new commitments.
Balaxi Pharma FY26 Consolidated Profit Drops 94% to ₹1.42 Cr; Receives New Plant License
Balaxi Pharmaceuticals reported a sharp decline in consolidated net profit for FY26, which fell to ₹1.42 crore from ₹25.07 crore in the previous year, primarily due to higher administrative and employee costs. Consolidated revenue also saw a slight dip of 7.6% to ₹270.17 crore. However, the company achieved a major operational milestone by securing a manufacturing license for its Jadcherla formulation plant on May 23, 2026. The facility is now ready for commercial production of Paracetamol and Piroxicam, with 40 more product permissions in the pipeline.
Key Highlights
Consolidated Net Profit for FY26 plummeted 94.3% YoY to ₹141.69 lakhs.
Consolidated Revenue from operations decreased to ₹270.17 crore in FY26 from ₹292.56 crore in FY25.
Received manufacturing license for the Jadcherla, Hyderabad facility on May 23, 2026, following successful CAPA verification.
Initiated manufacturing product permissions for 40 additional products to expand the commercial portfolio.
Standalone FY26 profit grew to ₹5.15 crore compared to ₹3.60 crore in the previous financial year.
👀 What to Watch
Investors should closely monitor the commercialization progress at the new Jadcherla plant, as its success is critical to recovering the significant drop in consolidated profitability. The stock remains a 'Watch' until the impact of the new manufacturing capabilities reflects in the bottom line.
Balaxi Pharma FY26 Consolidated Net Profit Plummets 94% to ₹1.42 Cr; New Plant License Received
Balaxi Pharmaceuticals reported a significant decline in its consolidated financial performance for FY26, with net profit crashing 94.3% YoY to ₹1.42 crore from ₹25.07 crore. Annual consolidated revenue also saw a contraction of 7.6%, falling to ₹270.17 crore. Despite the poor earnings, the company achieved a strategic milestone by obtaining a manufacturing license for its first pharmaceutical formulation plant in Hyderabad on May 23, 2026. The facility is now ready for commercial production of Paracetamol and Piroxicam, with 40 more product permissions in the pipeline.
Key Highlights
Consolidated FY26 Net Profit fell sharply to ₹1.42 crore from ₹25.07 crore in FY25.
Consolidated Revenue for FY26 declined 7.6% YoY to ₹270.17 crore.
Received Manufacturing License for the Jadcherla formulation facility on May 23, 2026.
Ready for commercialization of Paracetamol Tablet 500mg and Piroxicam Capsule 20mg.
Initiated process for obtaining manufacturing product permissions for 40 additional products.
👀 What to Watch
The massive erosion in profitability is a significant concern that may lead to short-term stock pressure. Investors should closely monitor the commercial ramp-up of the new Jadcherla facility as it is the primary catalyst for potential recovery in margins and revenue.
CRISIL Downgrades Balaxi Pharma to 'BBB/Stable' as Operating Margins Expected to Drop to 5%
CRISIL has downgraded Balaxi Pharmaceuticals' long-term rating from 'BBB+' to 'BBB', though it revised the outlook from 'Negative' to 'Stable'. The downgrade reflects significant pressure on profitability due to high marketing expenditures required for the company's shift toward institutional sales. Operating margins are expected to compress sharply to 5% in FY26 from 12% in FY25, while the working capital cycle remains stretched at 295 days. Despite these challenges, the company maintains a healthy capital structure with a gearing ratio of 0.25x and a net worth of Rs 204.9 crore.
Key Highlights
Long-term bank facility rating downgraded to 'CRISIL BBB' from 'CRISIL BBB+'
Operating margins projected to decline to 5% in FY26 from 12% in the previous fiscal year
9M FY26 net profit fell sharply to Rs 0.80 crore compared to Rs 16.43 crore in 9M FY25
Working capital cycle remains intensive with Gross Current Assets (GCA) at 295 days as of March 2025
Revenue concentration risk persists with over 50% of total revenue sourced from Angola
👀 What to Watch
Investors should monitor the company's ability to stabilize margins during its transition to institutional sales and track the progress of its Indian manufacturing facility expected in FY27. The significant drop in net profit and stretched working capital suggest short-term liquidity and profitability headwinds.
Balaxi Pharma Q3 FY26: Revenue at ₹72.54 Cr, PAT Declines to ₹0.31 Cr Amid Strategic Shift
Balaxi Pharmaceuticals reported a marginal 1% YoY decline in Q3 FY26 revenue to ₹72.54 crore, though it saw a strong 29% sequential recovery from Q2. Profit After Tax (PAT) dropped significantly to ₹0.31 crore from ₹5.36 crore last year, primarily due to higher operating costs and challenges in the Angola market's institutional segment. The company successfully completed the qualification and validation of its first pharmaceutical formulation facility in Hyderabad, marking a shift to an 'Asset Right' model. Despite near-term margin pressure, the LATAM region remains a strong growth driver with 13 new product registrations added this quarter.
Key Highlights
Revenue for Q3 FY26 stood at ₹72.54 crore, showing a 29% QoQ growth despite a 1% YoY dip.
PAT plummeted to ₹0.31 crore from ₹5.36 crore YoY due to elevated operating costs in institutional segments.
Total product registrations reached 948 across geographies, with 13 new registrations added in Q3.
The new Jadcherla formulation facility is now audit-ready, completing qualification and validation of equipment.
Gross margins moderated to 42% compared to 48% in the previous year's corresponding quarter.
👀 What to Watch
Investors should monitor the margin recovery as the new manufacturing facility begins to contribute to backward integration. The transition from 'Asset Light' to 'Asset Right' is a major strategic shift that may weigh on short-term profits but improve long-term supply chain control.
Balaxi Pharma Reports Zero Deviation in Utilization of ₹47.57 Crore Raised Funds
Balaxi Pharmaceuticals has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that funds raised through its preferential issue are being used as intended. Out of the total ₹47.57 crore raised via equity shares and convertible warrants, the company has utilized approximately ₹34.22 crore to date. The proceeds are primarily being deployed for the construction of a new pharmaceutical formulation plant in Jadcherla, Hyderabad, and for working capital requirements. The report indicates zero deviation from the objects stated during the fundraise, reflecting disciplined financial management.
Key Highlights
Total amount raised through preferential issue and warrant conversions is ₹47,56,92,250.
Cumulative funds utilized as of December 31, 2025, amount to ₹34,21,66,871.
The company reported zero deviation or variation in the use of proceeds for the reported quarter.
Funds are being utilized for capital expenditure on a new formulation plant in Jadcherla and general corporate purposes.
👀 What to Watch
Investors should view the lack of deviation as a positive sign of management integrity and focus on the upcoming Jadcherla plant as a key growth catalyst. Monitor the completion timeline of the facility to gauge future production capacity increases.
Balaxi Pharma Q3 Consolidated Net Profit Drops 94% YoY to ₹30.5 Lakhs; Jadcherla Plant Ready
Balaxi Pharmaceuticals reported a significant decline in consolidated net profit to ₹30.50 lakhs for Q3 FY26, compared to ₹536.28 lakhs in the same period last year. While consolidated revenue remained relatively stable at ₹72.54 crore, higher administrative and employee expenses impacted the bottom line. On a positive note, the company's first pharmaceutical formulation plant at Jadcherla is now fully ready for CDSCO inspection following successful test manufacturing. Additionally, the Company Secretary and Compliance Officer has resigned effective January 29, 2026.
Key Highlights
Consolidated Net Profit fell sharply to ₹30.50 lakhs in Q3 FY26 from ₹536.28 lakhs in Q3 FY25.
Consolidated Revenue from operations stood at ₹72.54 crore, a marginal decline from ₹73.29 crore YoY.
Jadcherla formulation facility is audit-ready for CDSCO inspection with successful test batches of Paracetamol and Piroxicam.
Consolidated EPS for the quarter dropped to ₹0.06 from ₹0.97 in the previous year's corresponding quarter.
Company Secretary Mohith Kumar Khandelwal resigned effective January 29, 2026.
👀 What to Watch
Investors should exercise caution as the sharp drop in profitability raises concerns despite stable revenues. The primary catalyst to watch is the successful CDSCO inspection and subsequent commercialization of the Jadcherla facility.
Balaxi Pharma Q3 Revenue Recovers to ₹72.5 Cr; Jadcherla Plant Ready for CDSCO Inspection
Balaxi Pharmaceuticals reported a consolidated revenue of ₹72.54 crore for Q3 FY26, representing a strong 29% sequential growth compared to Q2 FY26, though it remained flat year-on-year. Consolidated net profit saw a sharp decline to ₹30.50 lakhs from ₹5.36 crore in the previous year's corresponding quarter, primarily due to increased administrative and employee costs. A major operational milestone was achieved as the Jadcherla formulation plant reached full readiness for CDSCO inspection after successful test manufacturing. The company also announced the resignation of its Company Secretary, Mohith Kumar Khandelwal, effective January 29, 2026.
Key Highlights
Consolidated Revenue from operations for Q3 FY26 stood at ₹72.54 crore, up from ₹56.18 crore in Q2 FY26.
Consolidated Net Profit fell significantly to ₹30.50 lakhs from ₹5.36 crore in Q3 FY25.
Jadcherla formulation facility is 100% ready for CDSCO inspection with successful test batches of Paracetamol and Piroxicam completed.
Administrative expenses increased to ₹7.50 crore in Q3 FY26 compared to ₹6.15 crore in Q3 FY25.
Nine-month consolidated revenue for FY26 reached ₹199.46 crore with a net profit of ₹80.41 lakhs.
👀 What to Watch
Investors should focus on the upcoming CDSCO inspection results for the Jadcherla plant, as commercialization of this facility is the key catalyst for future margin improvement. While sequential revenue growth is positive, the sharp year-on-year profit compression warrants a cautious approach until operational leverage from the new plant kicks in.
